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Abstract Advanced therapies including stem cells are cur-
rently a major biotechnological development. Adult liver stem
cells can differentiate into hepatocyte like cells and be infused
in the recipient’s liver to bring a missing metabolic function.
These cells can be produced in large quantities in vitro.
Allogeneic stem cells are required to treat genetic diseases,
and this approach allows to use one single source of tissue to
treat different diseases and many recipients. Mesenchymal
stem cells can in addition play an immunomodulatory and
anti-inflammatory role and possibly prevent the accumulation
of fibrous tissue in the liver. From a regulatory point of view,
stem cells are considered as medicinal products, and must
undergo a pharmaceutical development that goes beyond the
research and proof-of-concept phases. Here, we review the
track followed from the first hepatocyte transplantation in
2000 to the next generation product issued from stem cell
technology, and the start of EMA approved clinical trials to
evaluate the safety and potency of liver stem cells for the
treatment of inborn errors of the liver metabolism.
Liver regenerative medicine aims to repair a functional defect
using cells, with metabolic diseases as the main indication
(Smets et al 2008; Sokal 2011; Nussler et al 2006; Dhawan
et al 2010).
Besides metabolic repair, stem cells are also able to restore
parenchymal integrity and structure, for example by reducing
fibrosis in chronic diseases (Forbes and Newsome 2012).
Mesenchymal stem cells can also reverse inflammation in
various toxic, autoimmune and alloimmune mediated liver
injuries (rejection, graft-versus-host reactions) (Forbes and
Newsome 2012; Le Blanc et al 2008; Sana et al 2013; Kean
et al 2013).
These different targets are based on very different princi-
ples of action. In the first case, the principle is based on
introducing in the deficient recipient liver healthy cells and
their enzyme content (Smets et al 2008; Sokal 2011; Nussler
et al 2006; Stéphenne et al 2005, 2006, 2012; Sokal et al 2003;
Lysy et al 2008a). In the second case, the cells introduced act
through cytokines and signaling factors as well as through
their immunoregulatory properties, which can modify cellular
interactions and re-establish a physiological balance between
parenchyma, inflammatory cells , and stel late or
myofibroblastic cells (Forbes and Newsome 2012; Sana et al
2013; Remberger et al 2008).
In metabolic diseases, cell grafts have now been developed
for around 15 years, the first clinical case being a Crigler-
Najjar patient treated with hepatocytes (Fox et al 1998). The
liver cells are obtained by enzymatic dissociation of the liver
using collagenase (Sokal et al 2003). Then, centrifugation
separates the parenchymal fraction, which contains the hepa-
tocytes (80% of the total), from the non-parenchymal fraction,
which contains, amongst others, stellate cells (8 %, precursors
of myofibroblasts), macrophages known as Kupffer cells,
epithelial duct cells and endothelial cells. When used for
clinical purpose, the process of collagenase perfusion and cell
isolation must be performed in approved tissue banks, work-
ing under the EU directive on tissues and organs. Whenever
stem cells are produced and manipulated, the EU regulation
on advanced therapies applies in addition to the EU directive
on tissues and organs.
Hepatocyte grafts have shown that cellular therapy is tech-
nically feasible and have established the proof of concept that
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it is possible to correct deficient enzymatic activity in the
recipient liver using cells.
The cells are delivered via a catheter placed in the portal
vein of the recipient, either by the percutaneous route, either
via an implantable catheter such as a Porth-a-Cath (Darwish
et al 2004). Direct intra-parenchymal injection has also been
tested successfully in pre clinical models, and the engraftment
of the cells can furthermore be improved by embedding the
cells in a matrix support such as hyaluronic acid or matrigel.
The percentage of liver cell replacement considered as
necessary to significantly improve metabolic disorders is
around 5% of the total liver mass, while 10% could normalize
the function. Asonuma showed that transplanting an auxiliary
liver corresponding to 12 % of the whole liver mass was as
efficient as a whole organ to correct hyperbilirubinemia in rat
(Asonuma et al 1992). In human, infusing 5 % of the estimat-
ed liver mass was sufficient to decrease significantly the
bilirubin level in Crigler-Najjar patients. (Fox et al 1998;
Lysy et al 2008b; Ribes-Koninckx et al 2012). In a mouse
model of phenylketonuria, 4.8 % to 9.3 % repopulation with
wild type hepatocytes allowed to decrease phenylalanine
levels by 68 %, considered as an appropriate therapeutic goal
in patients. Phenylalanine levels normalised in animals having
10 % liver repopulation (Harding and Gibson 2010). This
figure was corroborated in a child who achieved a significant
reduction of phenylalanine levels and half life after hepatocyte
transplantation, with 13 % and 6.6 % of phenylalanine hy-
droxylase activities measured in the post transplant liver bi-
opsies (Stéphenne et al 2012).
In a child with arginosuccinate lyase deficiency, significant
metabolic and clinical improvement was obtained with infu-
sion of 9 % of her liver mass, providing a 3 % de novo
measured enzyme activity (Stéphenne et al 2006). As another
example, living donor liver transplantation using a donor with
8 % of activity was able to correct the phenotype in a child
with citrullinemia. (Ban et al 2001).
The figure usually proposed that 5 % of the liver mass is
equivalent to 250 million cells per kg body weight is based on
estimations (Fox et al 1998), and seems probably by far
underestimated for small infants for who the classical doses
of 200 million cells par kg body weight is probably much less
than 5 % (Meyburg et al 2009a). The number of hepatocytes
in the human liver was calculated to be 2.41×1011 (241 billion
cells), accounting for 80 % of the total liver cell mass. Stellate
cells were calculated as 10 % of the hepatocyte mass; 5 % of
the hepatocyte mass would then be 12 billion cells for an adult
(Bianconi et al 2013). Most of the hepatocyte transplantation
programs deliver 2 to 4 billion cells to the recipient liver. Not
all transplanted cells engraft, as the cells are trapped in the
portal sinusoids and may be lost before crossing the endothe-
lial barrier. Drugs such as NSAIDs, nitroglycerin or prostacy-
clin (Bahde et al 2013) or radiation therapy are being tested to
facilitate this limiting step by opening the endothelial wall.
Hepatocytes, but also liver stem cells are poorly immuno-
genic and even tolerigenic; they do weekly express HLA class
I antigens and FAS, but not HLA-DR, nor FAS ligand nor co-
stimulatory molecules. In co-culture with allogeneic T cells,
they do not induce T cell activation nor proliferation, and
hepatocytes induce IL 10 production by dendritic myeloid
cells inducing naïve CD4+ T cell hypo-responsiveness (Sana
et al 2013). However, no precise clinical correlation allows at
this stage to withdraw immunosuppression in allogeneic liver
cell transplantation.
Given the limited percentage of cells delivered to patients,
it is therefore quite remarkable that functional improvements
have indeed been observed in various severe metabolic con-
ditions. The best results have been obtained in urea cycle
disorders (Stéphenne et al 2005, 2006; Meyburg et al 2009b;
Pareja et al 2013), in Crigler–Najjar syndrome (Lysy et al
2008a; Fox et al 1998; Pareja et al 2013; Ambrosino et al
2005), infantile Refsum’s disease (Sokal et al 2003), factor VII
deficiencies (Dhawan et al 2004), phenylketonuria (Stéphenne
et al 2012), glycogen storage disease type I (Pareja et al 2013;
Muraca et al 2002), Refsum disease (Sokal et al 2003) and
tyrosinemia (Pareja et al 2013). More mitigated results have
been observed in hypercholesterolemia and organic
acidemias.
The results of published cases of hepatocyte transplantation
have been recently reviewed (Jorns et al 2012). The main
limitation is that the duration of the clinical effect is limited,
and the benefit is lost after a period that varies between a few
months and a little more than 1 year, the maximum being
18 months. This observation means that the method is, at its
current stage, not attractive enough for patients and metabolic
doctors.
These case reports have been performed as proof of con-
cept cases and not within proper clinical trials. This innovative
medical practice is of course important at the emergence of
innovative therapies; however, only successful cases are pub-
lished, as physicians andmedical journals hardly report/accept
case reports, which do not show efficacy. It is therefore hard to
draw firm conclusions about safety and efficacy of the proce-
dure, and about the percentage of children who do effectively
benefit. In addition, adverse events are not systematically
collected for all cases performed and are not reported as it
would be in clinical trials; efficacy end points are in addition
not firmly established in advance, and the protocol is often
modified. This illustrates the richness and limitations of such
medical innovations, and the necessity to proceed to clinical
trials. For hepatocytes, Cytonet (Weinheim, Germany) is cur-
rently conducting such trial in urea cycle disorders, while
Promethera Biosciences (Mont-St-Guibert, Belgium) is
conducting trials with liver stem/progenitor cells in urea cycle
disorders and Crigler-Najjar syndrome.
Amongst the main adverse events to consider are the risk of
infectious agent transmission by fresh or even cryopreserved
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liver cells, which are comparable to agents transmitted
by whole liver graft (Bacteria, Epstein Barr virus,
Cytomegalovirus, ect.). Hence, hepatocyte transplantation
faces the same risk of causing post transplant lymphoprolifer-
ative diseases related to Epstein Barr virus.
In hepatocyte transplantation, each transplant procedure
requires more or less one source liver. Scarcity of donors is
not compatible with universal availability of this procedure,
which remains limited for a few patients in selected transplant
centers. Excess hepatocytes are commonly cryopreserved, but
these highly metabolically active cells are damaged by the
cryopreservation process, which causes mitochondrial respi-
ratory chain and membrane permeability damages (Stéphenne
et al 2007).
Liver stem/progenitor cells are obtained form primary he-
patocyte cultures. Plating the liver cells contained in the
parenchymal fraction for primary culture leads to the emer-
gence of different subpopulations of progenitor cells, which
can expand in culture and retain an ability to differentiate into
hepatocytes (Najimi et al 2007). Other candidate stem cell
types have been isolated from the liver using different culture
systems (Herrera et al 2006). This technology is the source of
a great deal of hope – producing cells in vitro on an almost
unlimited scale that can correct metabolic defects.
This in vitro expansion makes it possible to break away
from the dependency on organ donation, as the quantity of
source tissue necessary becomes negligible. In addition, this is
particularly compatible with a high scale pharmaceutical pro-
duction, and this gives a real prospect to bring cell-based
therapy to any patient in need in any metabolic centre.
Pharmaceutical development is also the guarantee to conduct
proper clinical trials, evaluating both safety and efficacy. Stem
or progenitor cells, produced in vitro in conditions of good
manufacturing practice, are classed as medicinal products in
Europe. They are known as advanced therapy medicinal prod-
ucts (ATMPs), and this status is defined by a specific
European framework (http://www.ema.europa.eu/ema/index.
jsp?curl=pages/regulation/general/general_content_000294.
jsp and a regulation issued in 2007 (n°1394/2007)
http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_
1394/reg_2007_1394_en.pdf. A specific committee has been
created at the European Medical Agency, the Committee for
Advanced Therapies (CAT) which is in charge of following
clinical development of all cell therapy products. Cell based
medicinal products can also be classified as orphan drugs if
the target is a disease with an incidence lower than 1/5000 live
births. For children, a Pediatric Investigation Planmust also be
designed and submitted for evaluation by the Pediatric
Committee. The European Medicinal Agency also offers sci-
entific advices and protocol assistance.
The european regulation authorizes hospital accredited tis-
sue banks to treat a few patients with ATMPs under the so
called “hospital exemption” rule. This is most important to
preserve, as it allows researchers and physicians to explore
new targets for cell therapies. Once the “invention” and proof-
of-concept phases have been passed, the clinical development
can only be considered at a pharmaceutical level and must
follow all regulatory steps for medicinal product market
authorization.
Thus was the implantation and repopulation of a recipient
liver by liver stem cells produced in vitro first shown in a
patient suffering from a urea cycle defect (Sokal et al 2013). In
this patient with a severe form of ornithine carbamoyl trans-
ferase deficiency, the recipient liver repopulation with donor
cells reached 3 to 5 %. This meant that infused cells had
proliferated, as the patient had received around 0.75 %% of
her liver mass. Such in vivo repopulation with the Adult
Derived Human Liver Stem Cells (ADHLSC) was previously
shown in uPA SCIDmice and SCIDmice, with differentiation
into hepatocyte like cells producing human protein and en-
zymes (Najimi et al 2007; Khuu et al 2013). When indium
labelled cells were infused in the portal vein in a patient with
type I glycogen storage disease, exclusive liver homing was
demonstrated up to the fifth day after infusion (Defresne et al
2014).
Development of ATMP must follow a strict production
plan, in an approved Good Manufactory Practice (GMP)
pharmaceutical environment. Release criteria must be
established and approved, including among other specifica-
tion the percentage of viability, the stability, level of impuri-
ties, precise cell identification markers, genetic stability and
potency to treat the target disease. The process must also be
adapted according to logistical requirements to deliver the cell
therapy medication to the patient’s bedside, which can be far
from the production site. The ideal scope will be to store the
product in the hospital pharmacy and perform the reconstitu-
tion of the drug substance at the patient’s bed, as currently
done for vaccines.
The potency is the cell metabolic capacity that matches the
disease targeted: production of urea, bilirubin conjugation,
glucose synthesis, production of coagulation factors, and so
on. Such potencies have been confirmed for adult-derived
human liver stem cells (ADHLSCs) (Najimi et al 2007;
Khuu et al 2011). Preclinical tests have also shown their
in vivo differentiation after transplantation in mice (Najimi
et al 2007; Khuu et al 2013).
Preclinical studies must evaluate the safety, absence of
oncogenicity, absence of toxicity, and biodistribution of the
cells (Scheers et al 2012). Before the end of the clinical
development, animal safety and biodistribution studies have
to be repeated in Good Laboratory Procedure (GLP)
environment.
Clinical studies must adhere to a development plan ap-
proved by European and national health authorities. The first
phase I/II studies aim to demonstrate safety and to gauge the
optimal dose of cells that needs to be infused (dose-finding
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studies). A second phase will serve to confirm dose and
efficacy. Long term safety follow up of the patients must be
organized and any adverse event collected and reported. As a
last step, the pivotal study, will aim to confirm efficacy with a
finalized production procedure and will enable to apply for
marketing authorization for the medication, delivered ulti-
mately by the European commission.
In the case of adult derived human liver stem cells, the
pharmaceutical development is ongoing; 20 patients have
been included in the phase I/II study, including Crigler-
Najjar and urea cycle disorders. Patients have been treated in
France, the UK, Italy, Belgium and Israel. This development is
performed by Promethera Biosciences (Mont-St-Guibert,
Belgium), a spinoff company of the Université Catholique
de Louvain.
The challenge, of course, will be to ascertain whether the
quantities of cells infused, which are theoretically around 1–
2% of themass of the recipient’s liver, will deliver a metabolic
benefit that is quantitatively sufficient. The mechanism also
lies in their capacity to survive on a long-term basis and to
proliferate, thus increasing metabolic efficacy over time.
As discussed above, in many metabolic diseases, a small
percentage of enzyme activity (a few per cent) can consider-
ably modify the phenotype of a patient, transforming a severe
disease that is difficult to control into a more favourable
phenotype, with a significant improvement in the quality of
life of the patient and the patient’s family.
For ADHLSC, the product is to be thought of as a treatment
that will be part of the therapeutic arsenal available to meta-
bolic doctors. Its function will be to improve the metabolic
balance of unstable patients for whom a liver transplant is not
planned. Although liver transplantation is a more radical
technique for correcting a metabolic defect, it is not without
risk, both in the short and long term. In a large retrospective
study of 323 children transplanted for urea cycle and organic
acid disorders, small children less than two years of age were
at increased risk of graft loss (78 % graft survival at 5 years),
whilst the 5 years graft survival in older kids was 88 %. Eight
children had died on the waiting list before receiving an organ
(Perito et al 2014). Long term graft survival can be hampered
by de novo immune hepatitis and chronic fibrosis of the graft
(Evans et al 2006; Andries et al 2001), while chronic or acute
rejection in adolescence can lead to re-transplantations as an
adult. The current shortage of organs creates difficulties to
define priorities (Donckier et al 2013). The survival rate of
paediatric liver transplantation averages 85 to 95 % at one
year, decreasing to 75–85 % in the longer term (Wallot et al
2002; Goss et al 1998; Bourdeaux et al 2009).
Stem cell based technology is a new biotechnology ap-
proach to treat patients with liver based metabolic diseases.
The proof of concept is made, and clinical trials are on-going
to design the best approach to deliver a sufficient quantity of
cells to change the clinical phenotype of the patients.
Preliminary data, including first in man treatments and on-
going clinical studies bring the expected evidence that this
therapy will break through in the coming years. Proper clinical
trials have now to emerge in continuity with single case
studies.
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